iShares Genomics Immunology and Healthcare ETF
$40.66−1.07 (−2.58%)
- Expense ratio
- 0.47%
- Fund size
- $277M
- 1Y return
- +82.3%
- Yield · Last 12 months
- 0.67%
- Holdings
- 50
- Volume · 30D
- 0.1M sh
- NAV per share
- $40.67
- 52W range
The ETF.net IDNA Grade
Score 56 of 100 sits in the B band. Bands: A ≥ 70, B ≥ 55, C ≥ 40, D ≥ 25, F < 25; the scale skips E.
Cost
What you pay to own it — the expense ratio plus trading frictions, ranked within its category.BScore 56Category rankMission
How faithfully it does the job it claims — tracking its mandate or index with minimal slippage.Not scoredRisk
How violently it can move — volatility, drawdown depth, and downside capture versus its category.BScore 64Category rankTradability
How cheaply and easily you can get in and out — liquidity, spread, and premium/discount stability.CScore 52Category rankHoldings
What it actually owns — the quality, breadth, and concentration of the underlying portfolio.CScore 48Category rankDurability
Whether it will still be here — the fund’s assets, age, flows, and issuer staying power.BScore 62Category rank
Our read on IDNA
BMost biotech ETFs hand you the US biotech index. IDNA goes narrower and wider at once: about 50 companies from developed and emerging markets, picked around genomics, immunology and bioengineering.
The Fund seeks to track an index of developed- and emerging-market companies positioned to benefit from long-term growth and innovation in genomics, immunology, and bioengineering.
Why people hold it
- The mandate is specific: an index of developed- and emerging-market companies tied to genomics, immunology and bioengineering, not a catch-all biotech basket.ishares.com
- 0.47% a year, a shade under the typical fund in its genomics-and-biotech peer group.
- About 50 holdings, so individual genomics and immunology names carry real weight instead of getting diluted inside a broad healthcare index.
- Running since 2019 under the iShares roof, and it stands in the upper half of its biotech and genomics peer group.
Worth knowing
- Concentration cuts both ways: about 50 stocks in one theme, so single-company clinical news lands harder here than in a broad healthcare fund.
- Smaller and less actively traded than the category's giants, so limit orders earn their keep. Emerging-market holdings add currency and local-market risk.
- Broad biotech index funds charge less, IBBQ at 0.19% and IBB at 0.44%; the extra basis points here buy the global genomics-and-immunology tilt.
IDNA Holdings
- Stocks
- 50
- 46%
- MRNA
Sectors
- Health Care100.0%
Geography
- United States64.65%
- Germany7.11%
- France6.15%
- Japan5.23%
- Switzerland4.60%
- Denmark4.13%
- United Kingdom2.86%
- Canada2.73%
- 2.53%
Developed 95% · Emerging 5%
IDNA Performance
Shows how $10,000 changes over the selected period, with cash distributions reinvested at the closing price on each ex-dividend date.
IDNA$18,229
Returns run to the Sep 22, 2026 close, with cash distributions reinvested. Each period starts on the same date that many months or years earlier. Periods over one year show the average yearly return.
| Period | IDNA |
|---|---|
| Year to date | +60.0% |
| 1 month | +4.1% |
| 3 months | +36.0% |
| 1 year | +82.3% |
| 3 years | +27.9% |
| 5 years | −4.3% |
| 10 years | — |
Calendar-year total return with cash distributions hypothetically reinvested at the ex-dividend date’s closing price. The current year shows year to date.
| Year | Return bar | IDNA |
|---|---|---|
| 2026 YTD | +60.0% | |
| 2025 | +17.3% | |
| 2024 | −0.7% | |
| 2023 | −7.6% | |
| 2022 | −42.3% | |
| 2021 | −4.0% | |
| 2020 | +54.3% |
IDNA in the news
IDNA Dividends
- 0.67%
- $0.28
- $0.13 per share
- Twice a year
Distribution history
| Ex-date | Pay date | Amount per share |
|---|---|---|
| Jun 15, 2026 | Jun 18, 2026 | $0.13 |
| Dec 16, 2025 | Dec 19, 2025 | $0.16 |
| Jun 16, 2025 | Jun 20, 2025 | $0.15 |
| Dec 17, 2024 | Dec 20, 2024 | $0.11 |
| Jun 11, 2024 | Jun 17, 2024 | $0.11 |
| Dec 20, 2023 | Dec 27, 2023 | $0.17 |
| Jun 7, 2023 | Jun 13, 2023 | $0.07 |
| Jun 9, 2022 | Jun 15, 2022 | $0.14 |
| Dec 13, 2021 | Dec 17, 2021 | $0.26 |
| Jun 10, 2021 | Jun 16, 2021 | $0.05 |
| Dec 14, 2020 | Dec 18, 2020 | $0.04 |
| Jun 15, 2020 | Jun 19, 2020 | $0.08 |
IDNA Risk
- 25.6%
How it’s calculated: standard deviation
The sample standard deviation of monthly total returns, multiplied by the square root of 12.
Uses up to 36 complete months, with at least 12 required. Total returns include reinvested distributions.
- 0.72
How it’s calculated: Sharpe ratio
Subtract each month’s Treasury-bill return from the fund’s monthly total return.
Divide the average of those excess returns by their sample standard deviation, then multiply by the square root of 12.
Uses up to 36 complete months, with at least 12 required. Each month uses the Treasury yield quoted at the end of the previous month.
- −68.1%
How it’s calculated: maximum drawdown
The largest percentage decline from an earlier peak, using total returns with reinvested distributions.
Uses up to five years through the last close, with at least 12 months required.
- 1.13
How it’s calculated: beta
The beta figure is supplied by FMP. The comparison index depends on the fund’s broad asset class.
IDNA Cost
0.47%
IDNA0.47%
- The middle half of Biotech & Genomics funds
- Median 0.47%
6 of the 15 Biotech & Genomics funds charge less.